|
ASKA Pharmaceutical Holdings Co., Ltd. is a holding company established in 2021 as the parent of Asuka Pharmaceutical. The group operates through four main business segments: pharmaceuticals, animal health, overseas operations, and other services. The pharmaceuticals segment focuses on the manufacturing and sale of human medicines, while the animal health segment produces veterinary drugs and feed additives. The overseas segment handles the production and distribution of human medicines in international markets, and the other segment includes clinical testing and medical devices. Key subsidiaries include Asuka Pharmaceutical, Asuka Pharmaceutical Medical, Asuka Animal Health, Ha Tay Pharmaceutical Joint Stock Company, and Ha Tay Pharmaceutical and Medical Equipment Joint Stock Company. Summarised from the annual report, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage aska-pharma-hd.co.jp |
| Sector Healthcare | IR page aska-pharma-hd.co.jp | |
|
Tags
human pharmaceuticals, veterinary drugs, feed additives, clinical testing, medical devices, Asuka Pharmaceutical, Asuka Pharmaceutical Medical, Asuka Animal Health, Ha Tay Pharmaceutical Joint Stock Company, Ha Tay Pharmaceutical and Medical Equipment Joint Stock Company
|
Press page aska-pharma-hd.co.jp/news |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 58.878B |
| Market cap (USD) | $ 367.993M |
| P/E | 11.17 |
| PEG | 1.30 |
| P/BV | 0.73 |
| P/S | 0.82 |
| P/OCF | 10.27 |
| P/FCF | 12.59 |
| Dividend yield | 2.9% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 7.4% |
| ROI | 6.3% |
| ROIC | 5.4% |
| Profit margin | 7.6% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | 8.6% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | Yes |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 24 |
| Quality score | 23.5% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 71.127B | 64.139B | 62.843B | 60.461B | 56.607B | 52.542B | 46.706B | 48.944B | 48.527B | 43.215B | 42.907B | 39.501B |
| Net profit | 5.424B | 5.101B | 7.545B | 4.238B | 4.29B | 649M | 1.744B | 2.388B | 2.944B | 701M | 1.193B | 495M |
| Free cash flow | 3.429B | -1.077B | 33M | 2.605B | 465M | -2.55B | 154M | -668M | 11.373B | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||
| Trade receivables (JPY) | — | 14.5B | 15.2B | 15.6B | 15.2B | 16B |
| ↳ YoY growth | +5.1% | +2.4% | -2.5% | +5.5% | ||
| Borrowings, current (JPY) | — | 1.72B | 3.44B | 4.98B | 4.46B | 3.27B |
| Borrowings, non-current (JPY) | — | 12.3B | 9.19B | 4.51B | 6.44B | 8.17B |
| Cash and deposits (JPY) | 10.5B | 12.1B | 14.5B | 13.7B | 10.6B | 10.1B |
| Intangible assets (JPY) | — | 6.18B | 4.47B | 2.88B | 6.99B | 8.87B |
| Net debt (borrowings + leases - cash) (JPY) | — | 1.94B | -1.88B | -4.25B | 299M | 1.31B |
| Cash flow detail | ||||||
| Operating cash flow (JPY) | — | 2.84B | 3.35B | 1.49B | 2.49B | 6.3B |
| Purchases of property, plant and equipment (JPY) | — | -579M | -461M | -1.32B | -2.96B | -2.55B |
| Purchases of intangible assets (JPY) | — | -1.8B | -285M | -133M | -602M | -325M |
| Change in receivables (cash effect) (JPY) | — | -1.36B | -742M | -370M | 1.2B | -867M |
| Change in inventories (cash effect) (JPY) | — | -687M | -2.63B | -2.71B | -2.68B | -2.68B |
| Change in payables (cash effect) (JPY) | — | 412M | -980M | 1.49B | 339M | -1.54B |
| Dividends paid (cash effect) (JPY) | — | -398M | -452M | -792M | -1.28B | -1.62B |
| Interest paid (cash effect) (JPY) | — | -58M | -51M | -41M | -51M | -222M |
| Income taxes paid (cash effect) (JPY) | — | -1.39B | -850M | -1.61B | -4.03B | -241M |
| Operating cash flow before change in receivables (JPY) | — | 4.2B | 4.09B | 1.86B | 1.28B | 7.17B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | — | 465M | 2.61B | 33M | -1.08B | 3.43B |
| Income detail | ||||||
| Research and development expense (JPY) | — | 3.6B | 4.23B | 4.73B | 7.03B | 7.06B |
| Total comprehensive income (JPY) | — | 4.98B | 5.98B | 8.13B | 5.22B | 6.58B |
| Comprehensive income to owners (JPY) | — | 4.98B | 5.98B | 8.13B | 5.22B | 6.59B |
| Provision for credit losses (JPY) | — | — | — | — | — | -23M |
| Credit cost ratio (credit losses / average receivables) (%) | — | — | — | — | — | 0.1% |
| Reported | Nov 8, 2021 | Jun 28, 2022 | Jun 27, 2023 | Jun 25, 2024 | Jun 20, 2025 | Jun 19, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| — | Continues | Continues 4514 (EDINET code E00929) as 4886: the same business renamed or reorganised. Its figures from before are this company's. |
ETFs Holding ASKA Pharmaceutical Holdings Co., Ltd.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| DISV | 0.01% | 47,100 | $ 645.084K | Nov 12, 2026 |
| DFIS | 0.01% | 36,800 | $ 504.015K | Nov 12, 2026 |
| DXIV | 0.00% | 700 | $ 9,587.24 | Nov 12, 2026 |
| DFIC | 0.00% | 21,900 | $ 299.944K | Nov 12, 2026 |
| DFAX | 0.00% | 13,300 | $ 182.158K | Nov 12, 2026 |
| DFSI | 0.00% | 900 | $ 12.326K | Nov 12, 2026 |
| DFAI | 0.00% | 13,700 | $ 187.636K | Nov 12, 2026 |
| AVDE | 0.00% | 3,500 | $ 47.638K | Nov 16, 2026 |
| AVDV | 0.00% | 21,800 | $ 296.719K | Nov 16, 2026 |
| AVDS | 0.00% | 800 | $ 10.889K | Nov 16, 2026 |